Biogen Pharmachem Industries (531752) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
5 Aug, 2026Executive summary
Board approved unaudited financial results for the quarter ended 30 June 2026.
Independent auditors conducted a limited review and found no material misstatements in the financial results.
Significant events and developments
Board meeting held on 5 August 2026 to consider and approve quarterly results.
Risk factors and uncertainties
Auditor's limited review provides moderate assurance but is not equivalent to a full audit; some significant matters may not be identified.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biogen Pharmachem Industries
- Revenue and net profit surged year-over-year, with a strong audit opinion and asset growth.531752
Q4 25/26 - Board approved unaudited results for Q3 and nine months ended Dec 2025; no audit issues found.531752Q3 25/26
- Q2 FY26 saw a sharp revenue drop, net loss, and higher equity, with strong cash flows.531752Q2 25/26
- Revenue and net profit rebounded sharply year-over-year, with EPS turning positive.531752Q1 25/26
- Q2 FY25 saw Biogen Pharmachem swing to a net loss with declining income and equity.531752Q2 24/25
- Q1 FY25 revenue turned negative and net loss reached ₹15.83 lakhs, reversing prior gains.531752Q1 24/25
- Q3 FY25 saw a net loss and major board changes at Biogen Pharmachem Industries.531752Q3 24/25
- FY25 saw Biogen Pharmachem return to profit with robust revenue growth and capital inflow.531752Q4 24/25